0.00Open0.04Pre Close0 Volume86 Open Interest6.50Strike Price0.00Turnover6415.96%IV13.29%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-18DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0636Delta0.0920Gamma186.25Leverage Ratio-34.2141Theta0.0000Rho-11.85Eff Leverage0.0000Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet